NSE: CAPLIPOINT · 20 November 2026
- Caplin Point Laboratories has fallen 15.10% over 5 trading sessions; today's move is -2.66%.
- Caplin Point Laboratories informed the exchange that the US FDA inspection at the facility of its subsidiary, Caplin Steriles Limited, has been classified as Official Action Indicated (OAI). The update highlights regulatory scrutiny regarding manufacturing standards at the sterile injectables facility. This disclosure is a key development for investors tracking the company's regulated market operations.
- Trading volume was 1.13 times the 20-day average daily volume.
Caplin Point Laboratories share price: 15.10% decline over 5 trading sessions
Caplin Point Laboratories Ltd. (CAPLIPOINT) declined by 2.66% today, settling at ₹2,029.10 compared to its previous close of ₹2,084.60. The stock opened at ₹2,113.60 and moved within a day's range of ₹2,020.00 and ₹2,126.00.
The broader market and sector indices showed positive momentum during the session, with the Nifty advancing 1.12% and the Nifty Pharma sector benchmark gaining 0.61%. Caplin Point's downward movement ran counter to the broader healthcare sector and headline index gains, reflecting ongoing stock-specific selling pressure that extends a broader near-term correction phase.
Recent company updates include an official NSE filing on November 17, 2026, regarding the classification of a US FDA inspection at subsidiary Caplin Steriles Limited's facility as Official Action Indicated (OAI). While this regulatory development provides notable context for market participants monitoring compliance and US market operations, it adds to sentiment headwinds following the company's financial results reported on November 12, 2026, for the quarter ended September 30, 2026.
1.65 lakh shares traded by 20 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.46 lakh shares (1.13 times). The five-day average daily volume was 2.76 lakh shares. Separately, the NSE report for 20 November 2026 showed 70,488 shares delivered, representing 42.70% of that day’s traded volume. The same report recorded 17,905 trades.
The stock declined by 2.66% amidst positive broader market and sector performance, diverging from the Nifty Pharma index gain. Recent negative regulatory developments regarding a subsidiary's US FDA inspection status provide relevant sentiment background, compounding recent downward momentum.
Latest Company Developments
Caplin Point Laboratories informed the exchange that the US FDA inspection at the facility of its subsidiary, Caplin Steriles Limited, has been classified as Official Action Indicated (OAI). The update highlights regulatory scrutiny regarding manufacturing standards at the sterile injectables facility. This disclosure is a key development for investors tracking the company's regulated market operations.
OAI classifications at key manufacturing subsidiaries can impact timelines for pending US abbreviated new drug applications (ANDAs) and regulatory approvals.
The company submitted its unaudited financial results for the quarter and half-year ended September 30, 2026, to the stock exchanges. Management also hosted an earnings conference call and released an updated investor presentation detailing operating performance. These disclosures outline ongoing revenue growth and operational metrics across core emerging markets and regulated segments.
Quarterly earnings results and management commentary form the primary baseline for assessing valuation and operational growth trajectory.
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.
Classification of US FDA Inspection at the facility of Caplin Steriles Limited (Company's Subsidiary) as OAI.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 1.64% on 30 September 2026. This compares with 2.03% on 30 June 2026, a change of -0.39 percentage points.
The filing reported 20 MF/UTI holders.
What to Watch Next
- Company response or remediation updates regarding the Caplin Steriles US FDA OAI classification
- Progress on US ANDA filings and regulatory approvals for the injectables business
- Delivery volume trends relative to the 20-day average volume of 1.13x observed today
- Upcoming operational milestones and management guidance tracking performance in Latin American and regulated markets
Other Dated Coverage
- Caplin Point Laboratories Share Price Today: Falls 11.55% in 2 Trading Sessions | 18 November 2026 — 18 November 2026
- Caplin Point Laboratories Share Price Today: Why CAPLIPOINT Is Rising 0.56% | 29 October 2026 — 29 October 2026
More Caplin Point Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Caplin Point Laboratories company news?
Caplin Point Laboratories informed the exchange that the US FDA inspection at the facility of its subsidiary, Caplin Steriles Limited, has been classified as Official Action Indicated (OAI). The update highlights regulatory scrutiny regarding manufacturing standards at the sterile injectables facility. This disclosure is a key development for investors tracking the company's regulated market operations.
How strong was Caplin Point Laboratories’s trading volume?
1.65 lakh shares traded, 1.13 times the 20-day average daily volume. The price and volume data are dated 20 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.
